iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread

Doylestown, Pennsylvania – IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company that is committed to becoming a leader in topical drug development with specialization in ophthalmology is currently developing treatment and prevention strategies against the novel SARS-CoV-2, also known as, COVID-19.

IVIEW’s unique Povidone-Iodine (PVP-I) formulation has been used as a powerful antiseptic against infections such as Acute Adenoviral Conjunctivitis and Chronic Rhinosinusitis. As the community knows, there is a significant unmet medical need in treating patients affected by COVID-19 and curb the spread of COVID-19 transmission. IVIEW initiated multiple projects to fight this global pandemic. IVIEW hopes to apply their innovative in-situ gel sustain release formulation technology using PVP-I’s broad spectrum anti-microbial, anti-viral, and anti-fungal properties against the novel COVID-19.

PVP-I is known to show high viricidal efficacy against enveloped viruses, e.g. SARS-CoV,[i] MERS-CoV, Ebola virus,[ii] and influenza virus A (H1N1), rotavirus, and murine norovirus (MNV),[iii][iv][v] as well as other non-enveloped human viruses, e.g. adenovirus and polyomavirus. More recently, it was found that PVP-I is efficacious in preventing the infection and spread against Ebola virus disease.[vi] Due to similarity among enveloped viruses, PVP-I is expected to show viricidal efficacy against SARS-CoV-2.[vii]

IVIEW’s Phase II product, IVIEW-1201, a PVP-I gel-forming ophthalmic drop used to treat Acute Adenovirus Conjunctivitis could potentially be used to treat and prevent COVID-19 infections in the eye. The pharmaceutical company has been working closely with China’s CDE since January 2020 to initiate clinical trials. In addition, IVIEW is in the process of developing a proprietary PVP-I gel-forming sustain release nasal spray for long-acting viricidal effect against COVID-19. The short residual effect of water-soluble povidone iodine on nasal mucosa is undesirable and would require frequent and multiple administration to maintain the viricidal efficacy, thus rendering it inconvenient in a global pandemic as an infection prevention strategy. Therefore, developing a safe, non-toxic and long-acting PVP-I nasal spray is an urgent medical need to protect people from the COVID-19 infection to block the transmission through nasal cavity. IVIEW is collaborating with Institute for Antiviral Research at Utah State University to conduct in-vitro viricidal assay using IVIEW’s novel PVP-I formulations against the COVID-19 virus. The development of a dilute PVP-I nasal formulation would be a great asset in fighting the COVID-19 pandemic by treating and preventing further progression of the debilitating infection that may lead to dangerous symptoms.

References

[i]Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006;212 Suppl 1:119-23.

[ii]Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis. 2015 Sep 17;15:375. doi: 10.1186/s12879-015-1111-9.

[iii]Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Infect Dis Ther. 2018 Jun;7(2):249-259. doi: 10.1007/s40121-018-0200-7. Epub 2018 Apr 9.

[iv]Eggers M, Koburger-Janssen T, Ward LS, Newby C, Müller S. Bactericidal and Virucidal Activity of Povidone-Iodine and Chlorhexidine Gluconate Cleansers in an In Vivo Hand Hygiene Clinical Simulation Study. Infect Dis Ther. 2018 Jun;7(2):235-247. doi: 10.1007/s40121-018-0202-5. Epub 2018 May 14.

[v]Matsuhira T, Kaji C, Murakami S, Maebashi K, Oka T, Takeda N, Katayama K. Evaluation of four antiseptics using a novel murine norovirus. Exp Anim. 2012;61(1):35-40.

[vi]Eggers M, Eickmann M, Kowalski K, Zorn J, Reimer K. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis. 2015 Sep 17;15:375. doi: 10.1186/s12879-015-1111-9.

[vii]FireBrick Pharma. (2020, February 21). Australian Nasal Spray Inactivates Coronavirus. Retrieved from FireBrick Pharma website: https://www.firebrickpharma.com/australian-nasal-spray-inactivates-coronavirus/.

About iVIEW Therapeutics Inc.

iView Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of ophthalmology therapeutics. iVIEW Therapeutics is headquartered in Pennsylvania Biotechnology Center of Bucks County with its China subsidiary located in Hengqin, Zhuhai city. For additional information on iView, please visit the Company’s website at www.iviewtherapeutics.com.

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2020 iVIEW Therapeutics, Inc. All rights reserved.